Literature DB >> 1320781

Impact of specimen handling and storage on detection of hepatitis C virus RNA.

M P Busch1, J C Wilber, P Johnson, L Tobler, C S Evans.   

Abstract

Direct detection of hepatitis C virus (HCV) RNA in serum or plasma is useful for validating the performance of anti-HCV assays and for the discrimination of persons with persistent HCV infections from those with resolved infections. Quantitation of HCV RNA may also be useful for disease prognosis and therapeutic monitoring. Previous studies have reported detection of HCV RNA in 50 to 70 percent of blood donors who were positive on anti-HCV supplemental tests. There is concern that specimen processing and storage conditions might influence the stability, and hence the detectability, of HCV RNA. To address this concern, the rate of detection of HCV RNA by the polymerase chain reaction (PCR) using donor pilot tube sera (PTS) previously subjected to routine donor screening and supplemental testing was compared with HCV PCR results obtained with fresh-frozen plasma (FFP) derived from the same donations. All 16 anti-HCV supplemental test-positive donations evaluated were HCV RNA positive with FFP, whereas only 10 (62.5%) were positive with PTS (p = 0.024). None of 11 FFP or PTS samples from HCV enzyme immunoassay-reactive donations not confirmed by supplemental anti-HCV assays tested positive for HCV RNA. Direct comparison of sample type (serum vs. plasma) and various storage conditions using specimens from two seropositive donors showed that room-temperature storage results in marked reduction in HCV RNA signal, while replicate freezing and thawing caused a moderate reduction. These data indicate that well-controlled sample processing and storage conditions are critical to the sensitive and potentially quantitative analysis of HCV RNA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320781     DOI: 10.1046/j.1537-2995.1992.32592327714.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  20 in total

1.  Stability of hepatitis C virus, HIV, and hepatitis B virus nucleic acids in plasma samples after long-term storage at -20°C and -70°C.

Authors:  Cristina Baleriola; Harpreet Johal; Brendan Jacka; Sandra Chaverot; Scott Bowden; Sara Lacey; William Rawlinson
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

2.  PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.

Authors:  Debbie L Seem; Ingi Lee; Craig A Umscheid; Matthew J Kuehnert
Journal:  Public Health Rep       Date:  2013-07       Impact factor: 2.792

3.  Inactivation and survival of hepatitis C virus on inanimate surfaces.

Authors:  Juliane Doerrbecker; Martina Friesland; Sandra Ciesek; Thomas J Erichsen; Pedro Mateu-Gelabert; Jörg Steinmann; Jochen Steinmann; Thomas Pietschmann; Eike Steinmann
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

4.  Assessment of hepatitis B virus DNA stability in serum by the Chiron Quantiplex branched-DNA assay.

Authors:  M Krajden; L Comanor; O Rifkin; A Grigoriew; J M Minor; G F Kapke
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

5.  Use of whole blood specimens for routine clinical quantitation of hepatitis C virus RNA does not increase assay sensitivity.

Authors:  L Cook; A M Ross; G B Knight; V Agnello
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

6.  Ebola Preparedness: Diagnosis Improvement Using Rapid Approaches for Proficiency Testing.

Authors:  Katherine A Lau; Torsten Theis; Joanna Gray; William D Rawlinson
Journal:  J Clin Microbiol       Date:  2016-12-14       Impact factor: 5.948

7.  Hepatitis C screening and blood safety.

Authors:  K Sazama
Journal:  West J Med       Date:  1993-03

8.  Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: comparison with nested amplification and antibody testing.

Authors:  K K Young; J J Archer; O Yokosuka; M Omata; R M Resnick
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

9.  Immunosuppressive therapy and hepatitis C virus infection: the clinical course of liver disease.

Authors:  W H Grotz; T H Peters; H J Schlayer; G Kirste; H Berthold; H Felten; P J Schollmeyer; J W Rasenack
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

10.  Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus.

Authors:  H T Cuypers; D Bresters; I N Winkel; H W Reesink; A J Weiner; M Houghton; C L van der Poel; P N Lelie
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.